Sino-Fugen Biotechnology

Sino-Fugen Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, focused on developing next-generation T-cell receptor (TCR) engineered T-cell therapies for the treatment of solid tumors. The company utilizes its proprietary TCR discovery and optimization platform to develop a pipeline of candidates targeting cancer-testis antigens, including NY-ESO-1 and MAGE-A3/A4. Its lead program, SFJ-001, is a TCR-T therapy currently in Phase 1 clinical trials for patients with NY-ESO-1 positive advanced synovial sarcoma and liposarcoma. Sino-Fugen's mission is to harness the power of the immune system to provide effective therapeutic options for cancer patients with limited treatment alternatives. The company maintains a state-of-the-art GMP manufacturing facility to support its clinical development programs.